K&A advised Jamjoom Pharmaceuticals Company on its acquisition of a pharmaceutical manufacturing facility in KAEC, Saudi Arabia, from Pfizer Saudi.
The transaction involved the transfer of a fully operational pharmaceutical manufacturing facility for oral solid dosage products, together with associated assets, employees, contracts and transitional arrangements to ensure continuity of operations. The facility forms part of Pfizer’s established manufacturing presence in the Kingdom and represents a significant industrial asset within Saudi Arabia’s pharmaceutical sector. The transaction aligns with national priorities around localisation, industrial development and supply chain resilience, while enhancing access to high-quality healthcare solutions across the Middle East and Africa.
K&A advised on all legal aspects of the transaction, including structuring and negotiation of the asset acquisition, regulatory considerations, and transitional arrangements. Completion of the transaction remains subject to customary conditions precedent, including obtaining the necessary regulatory approvals.
The K&A team was led by Partner Omar Iqbal and Associate Nabeel Sarwar, supported by Associates Duaa Amer, and Yousif Latifa .
This transaction further reinforces K&A’s position as a leading adviser on strategic Pharmaceutical and Biotechnology transactions in Saudi Arabia, particularly those involving complex M&A, asset transfers and cross-border counterparties. It follows the firm’s continued recognition as a Band 1 firm for Corporate / Commercial and M&A by Chambers Global 2026.
